% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • giguy_1999 giguy_1999 Dec 19, 2012 4:05 PM Flag

    What is different NOW

    is that we know that this drug can cause deaths. When the drug came out and got FDA approval they said that the Stevens-Johnson reaction was reversible in the patients who had it. We now know that is not the case.

    Now HCV is a chronic disease, and you are taking the drugs to prevent death many years from now.

    But you have a certain probability of dying on this therapy.

    Very difficult to advise your patient to take this when other alternatives- non-deadly- are available or on the horizon

    Doctor's most important motto:

    First do no harm.

    That's why Incivek is doomed, IMO.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • it's less than 1% and the press release said when the rash is seen, the drug is stopped and patents recover. Man, you must have gotten it up the butt by some VRTX manager and were fired.

    • Incivek was always doomed; the strategy as they have stated is to wring as much revenue as they can out of Incivek while understanding that all oral therapies are the future. Incivek has no strategic importance for the company. This will, however, affect revenues to some degree in 2013. Hastening European funding of Kalydeco could reverse the effect on revenue.

90.38+1.19(+1.33%)May 27 4:00 PMEDT